Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Common Equity (2016 - 2025)

Bio-Techne has reported Common Equity over the past 17 years, most recently at $2.0 billion for Q4 2025.

  • Quarterly results put Common Equity at $2.0 billion for Q4 2025, down 3.25% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (down 3.25% YoY), and the annual figure for FY2025 was $1.9 billion, down 7.25%.
  • Common Equity for Q4 2025 was $2.0 billion at Bio-Techne, up from $2.0 billion in the prior quarter.
  • Over the last five years, Common Equity for TECH hit a ceiling of $2.1 billion in Q3 2024 and a floor of $1.5 billion in Q1 2021.
  • Median Common Equity over the past 5 years was $1.9 billion (2023), compared with a mean of $1.9 billion.
  • Biggest five-year swings in Common Equity: grew 19.88% in 2021 and later decreased 8.08% in 2025.
  • Bio-Techne's Common Equity stood at $1.7 billion in 2021, then grew by 7.32% to $1.8 billion in 2022, then increased by 7.47% to $2.0 billion in 2023, then increased by 5.85% to $2.1 billion in 2024, then fell by 3.25% to $2.0 billion in 2025.
  • The last three reported values for Common Equity were $2.0 billion (Q4 2025), $2.0 billion (Q3 2025), and $1.9 billion (Q2 2025) per Business Quant data.